Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.

Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, Bergqvist PB, Khoo V

Clinical oncology (Royal College of Radiologists (Great Britain))17 Dec 2012Cited by 56 (Europe PMC)

PMID23257248DOI10.1016/j.clon.2012.09.010PepBankPUB-23257248

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with prostate cancer, prostate volume changed by -36.0 ± 14.5% with degarelix versus -35.3 ± 16.7% with goserelin plus initial bicalutamide.
In plain wordsIn men with prostate cancer, prostate volume reductions were similar with degarelix and goserelin plus bicalutamide.
Peptide
Degarelix
Outcome
No significant changeTotal prostate volume reduction
Study
n = 244
Comparator
Goserelin plus initial bicalutamide
Analysis
Primary
Outcome group
Tumor growth · Kidney and urinary
Studied dose
240 mg initial, then 80 mg monthly · 12 weeksAs given in this study (human).
Measurements
Prostate volume change
−36%
degarelix
Prostate volume change
−35.3%
goserelin
Adjusted difference
−0.3%
95% confidence interval -4.74 to 4.14
Source sentences
Summary
The total prostate volume decreased significantly from baseline to week 12 in both treatment groups, reaching -36.0 ± 14.5% in degarelix-treated patients and -35.3 ± 16.7% in goserelin-treated patients (adjusted difference: -0.3%; 95% confidence interval: -4.74; 4.14%).
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients received treatment with either monthly degarelix (240/80 mg) or goserelin (3.6 mg) for 12 weeks, the latter patients also receiving bicalutamide (50 mg) for 17 days initially.
Report a problemFND-2325724801
02HumanRandomized controlled trialEfficacy outcome
In men with prostate cancer, IPSS decreases of ≥3 points occurred in 37% with degarelix versus 27% with goserelin plus initial bicalutamide (P = 0.21).
In plain wordsIn men with prostate cancer, symptom response rates did not differ significantly between degarelix and goserelin plus bicalutamide.
Peptide
Degarelix
Outcome
No significant changeIPSS decrease of at least three points
Study
n = 244
Comparator
Goserelin plus initial bicalutamide
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
240 mg initial, then 80 mg monthly · 12 weeksAs given in this study (human).
Measurements
IPSS responder proportion
37%
degarelix
IPSS responder proportion
27%
goserelin
Source sentences
Summary
At the end of the therapy, more degarelix- than goserelin-treated patients reported International Prostate Symptom Score decreases of ≥3 points (37% versus 27%, P = 0.21).
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients received treatment with either monthly degarelix (240/80 mg) or goserelin (3.6 mg) for 12 weeks, the latter patients also receiving bicalutamide (50 mg) for 17 days initially.
Report a problemFND-2325724802
03HumanRandomized controlled trialEfficacy outcome
In prostate cancer patients with baseline IPSS ≥13, IPSS decreased by 6.04 with degarelix versus 3.41 with goserelin plus initial bicalutamide (P = 0.06).
In plain wordsIn symptomatic prostate cancer patients, symptom scores fell more with degarelix than goserelin plus bicalutamide (6.04 versus 3.41 points, P = 0.06).
Peptide
Degarelix
Outcome
DecreaseIPSS decrease with baseline IPSS at least thirteen
Study
n = 70
Comparator
Goserelin plus initial bicalutamide
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
240 mg initial, then 80 mg monthly · 12 weeksAs given in this study (human).
Measurements
IPSS decrease
6.04 points
degarelix n = 53
IPSS decrease
3.41 points
goserelin n = 17
Source sentences
Summary
In addition, in patients with a baseline International Prostate Symptom Score of ≥13, the magnitude of the decrease was larger in degarelix- (n = 53) versus goserelin-treated patients (n = 17) (6.04 versus 3.41, P = 0.06).
1 context sentence(design, population, supporting numbers)
Summary · context
Eligible patients received treatment with either monthly degarelix (240/80 mg) or goserelin (3.6 mg) for 12 weeks, the latter patients also receiving bicalutamide (50 mg) for 17 days initially.
Report a problemFND-2325724803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00833248

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Ferring Pharmaceuticalsn = 246Apr 2009 to Sept 2011

Prostate Cancer

Trial page ClinicalTrials.govUpdated 4 Oct 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.